Profit

NSE Symbol: | BSE Code: | ISIN: | Sector:

  • Add to Portfolio
  • Add to Watchlist
  • Add to Alert
  • Add to Message
Add to Portfolio
NSE
2724.85
Change Change %
-2.55 -0.09%

Updated:18 Oct, 2019, 15:55 PM IST

BSE
2721.25
Change Change %
-5.40 -0.20%

Updated:18 Oct, 2019, 16:01 PM IST

Period:

Previous Close
Day's Open
Volume Traded (in 000's)
Value Traded (in Cr)

Day's Range

2710.05 2744.95

52 Wk Range

1872.95 2964.00
Period:

Previous Close
Day's Open
Volume Traded (in 000's)
Value Traded (in Cr)

Day's Range

2711.002744.25

52 Wk Range

2017.20 2965.20

Compare Price performance of vs. Peer Companies

From sector

Compare with Peers on Key Fundamentals and Financials

Color code for Price performance of and Peer companies

  • 5% and above
  • 2% to 5%
  • 0.5% to 2%
  • -0.5% to 0.5%
  • -2% to -0.5%
  • -5% to -2%
  • -5% and below
 

's Latest Research Report

Brokerage/Analyst Report Date Call Price@Call Target Current Status Report
Nomura
-
26-09-2019 Buy 2775.25 3284.00 Open Details
Nomura
-
30-07-2019 Buy 2581.50 3285.00 Closed Details
Elara Capital
-
04-02-2019 Sell 2805.00 2759.00 Target Hit Details
Edelweiss
-
30-06-2018 Buy 2235.05 3350.00 Closed Details
Nomura
-
30-01-2018 Buy 2330.00 3238.00 Closed Details

More from Research Reports »

Dr. Reddys Lab's Key Fundamentals

Parameter Values
Market Cap (in ₹ Cr.) 45,261.67
Earning Per Share (EPS TTM) (₹) 78.02
Price To Earnings (P/E) Ratio 34.93
Book Value Per Share (₹) 706.34
Price To Books (P/B) Ratio 3.86
EBIT Margin (%) 8.12
PAT Margin (%) 6.06
ROCE (%) 5.36
PAT Growth (%) -59.04
Total Debt to Equity (D/E) Ratio 0.22

More from Key Fundamentals »

Dr. Reddys Lab's Financial Summary

Parameter MAR'18
(₹ Cr.)
MAR'17
(₹ Cr.)
YoY
%Change
Balance Sheet:
Share Capital 83.00 82.90 0.12%
Total Non-Current Liabilities 479.50 506.50 -5.33%
Total Current Liabilities 4,719.90 4,258.00 10.85%
Total Liabilities 17,007.20 16,365.10 3.92%
Total Non-Current Assets 7,968.70 7,771.30 2.54%
Currents Investments 1,682.80 1,299.10 29.54%
Cash and Bank 120.70 66.80 80.69%
Total Current Assets Excluding Current Investments 7,355.70 7,294.70 0.84%
Total Assets 17,007.20 16,365.10 3.92%
Profit and Loss:
Gross Sales 9,359.30 9,719.80 -3.71%
Net Sales 9,359.30 9,719.80 -3.71%
PBIDT (Excl OI) 1,272.60 1,678.60 -24.19%
PAT 566.90 1,384.10 -59.04%

More from Financial Summary »

Dr. Reddys Lab's Shareholding Pattern

's Futures and Options Quotes

Contract
Expiry Date
Type Current price Change Change % Premium / Discount
DRREDDY
31-10-2019
FUTSTK
2721.10 -7.25 -0.27% -3.75
DRREDDY
28-11-2019
FUTSTK
2739.60 0.05 0.00% 14.75
DRREDDY
26-12-2019
FUTSTK
2700.00 0.00 0.00% -24.85

More from Futures and Options Quotes »

Dr Reddy's Laboratories

Dr Reddy's Laboratories is a pharmaceuticals company headquartered in Hyderabad. Dr Reddy's is one of the world's largest manufacturers of APIs (Active Pharmaceuticals Ingredients). Dr Reddy's Laboratories offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's Laboratories' major markets include the US, India, Russia & CIS (Commonwealth of Independent States) countries, and Europe. With Global Generics being its biggest business driver, Dr Reddy's Laboratories offers more than 200 generic drugs. In FY17, Dr Reddy's Laboratories registered a net profit of Rs 1,384 crore over revenue of Rs 9,720 crore. As of September 2017, the promoter group of Dr Reddy's Laboratories held a 26.77 per cent stake in the company with the public holding the remaining 73.23 per cent.


Dr Reddy's Laboratories shares

Dr Reddy's Laboratories shares trade with the symbol DRREDDY on stock exchanges BSE and NSE.


History

Dr Reddy's Laboratories was founded by Dr K Anji Reddy in 1984.

Background

North America Generics remain the most significant market for Dr Reddy's Laboratories comprising 55 per cent of the global generics topline, according to the company's annual report of 2017. Its revenue from India for FY2017 grew at 9 per cent year-on-year to Rs 2,310 crore.


Registered office

Dr Reddy's Laboratories, 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana-500034

Post your comments about Dr. Reddys Lab

Top